EUVIMED · CrossrefZeitschrift
Cytotherapy
ISSN 1465-3249 · Elsevier BV
Neueste Artikel
Mesenchymal stromal cells for progressive multiple sclerosis: current evidence and translational challenges
Consensus perspectives on quality control and safety strategies for the clinical translation of induced pluripotent stem cell−derived cell therapies
Building a Clinical-Grade Allogenic Adipose-Derived MSC Therapy for Epidermolysis Bullosa
Three-dimensional mesenchymal stromal cell spheroids potently suppress neutrophil extracellular trap formation
Trajectory clustering of longitudinal donor chimerism after pediatric hematopoietic stem cell transplantation for non-malignant disorders
Model-predicted fludarabine exposure and outcomes after tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia
A regulatory gap: addressing visible particle control in cell and gene therapies through a risk-based framework
Pre-clinical validation of OSCAR-3 mRNA-based CAR T cells for targeting osteosarcomas
Comparative analysis of advanced therapy regulatory frameworks in Latin America: perspectives from the ISCT South and Central America Legal and Regulatory Affairs Committee
Swissmedic Innovation Office: early regulatory engagement to accelerate ATMP clinical development—regulatory insights and recommendations
Integrated T-cell enrichment, static transduction, and expansion in gas-permeable bioreactors for adoptive cell therapy
Multi-site validation and applicability assessment of a practical three-dimensional colony formation assay for detecting malignantly transformed cells
Phenotype-outcome standards must guide personalized CAR-T manufacturing
Pretransplant infection associated with inferior survival after TCRαβ/CD19-depleted haploidentical HSCT in pediatric nonmalignant disorders
Evaluation of pluripotent stem cell-derived myeloid line-based chimeric antigen receptor macrophage-like cells identifies limited in vivo persistence
Enhanced antitumor efficacy through combined chimeric antigen receptor T cell therapy and CD40 stimulation in syngeneic solid tumor models
Automating chimeric antigen receptor T-cell manufacturing across distinct platforms delivers similar cell quality, phenotype and function
Hypoxia during GPC2-CAR T-cell manufacturing compromises cell expansion and cytotoxic capacity
Early detection of chimeric antigen receptor-T-associated neurotoxicity via cytokine monitoring in serum
Aims and Scope
Editorial Board
Table of Contents
Subscription information
From classroom to cleanroom: building a skilled cell and gene therapy workforce
Safety and tolerability of topical mesenchymal stromal cell secretome in persistent corneal epithelial disease—a phase 1b clinical trial
Establishment and multisite evaluation of a MOLT-4 cell-based IL-2-independent growth assay to detect transformed cells in T-cell products
iPSC-derived engineered immune cells: a therapeutic platform
Compassionate and Emergency Use Cellular Therapy Products: Regulatory, Operational, and Quality Considerations
Rapid epigenetic analysis for quantification of iPSC pluripotency from dried cell spots
Enhancing NK cell cytotoxicity with innate cell engagers as an alternative to CAR-NK cells
EUVIMED